Regeneron Pharmaceuticals, Inc.

REGN

US75886F1075

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 10/09/2024 BST			5-day change	1st Jan Change
1,136.35 ^USD	-0.74%		-2.78%	+29.38%

07:54am	Sanofi's Dupixent Drug Achieves Improvement for Skin Diseases	DJ
09-09	Regeneron Pharmaceuticals' Factor XI Antibodies to 'Generate More Attention,' RBC Says	MT

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Regeneron Pharmaceuticals, Inc.

Sanofi's Dupixent Drug Achieves Improvement for Skin Diseases	06:54am	DJ
Regeneron Pharmaceuticals' Factor XI Antibodies to 'Generate More Attention,' RBC Says	09-09	MT
RBC Raises Price Target on Regeneron Pharmaceuticals to $1,282 From $1,250, Keeps Outperform Rating	09-09	MT
Bayer's OcuClick Secures Approval from European Medicines Agency	09-09	MT
RBC Raises Price Target on Regeneron Pharmaceuticals to $1,282 From $1,250, Keeps Outperform Rating	09-09	MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,178,730, According to a Recent SEC Filing	09-05	MT
Transcript : Regeneron Pharmaceuticals, Inc. Presents at Wells Fargo 2024 Healthcare Conference, Sep-05-2024 12:45 PM	09-05
RBC Capital Adjusts Price Target on Regeneron Pharmaceuticals to $1,250 From $1,240	09-05	MT
Transcript : Regeneron Pharmaceuticals, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 11:30 AM	09-04
Sonoma Biotherapeutics Receives $45 Million Milestone Payment from Regeneron Under Ongoing Collaboration	09-04	CI
Regeneron Pharmaceuticals Insider Sold Shares Worth $6,846,262, According to a Recent SEC Filing	08-29	MT
Regeneron Pharmaceuticals Gets European Commission Approval for Ordspono	08-26	MT
Regeneron Pharmaceuticals, Inc Announces Ordspono (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma	08-26	CI
Piper Sandler Adjusts Price Target on Regeneron Pharmaceuticals to $1,242 From $1,166, Maintains Overweight Rating	08-23	MT
Global markets live: Novo Nordisk, Walmart, Target, Keysight Technologies, Coty...	08-21
All eyes on the Fed's minutes	08-21
Regeneron Pharmaceuticals Says FDA Approval of Multiple Myeloma Treatment Slowed Over Factory Concerns	08-21	MT
Regeneron Provides Update on Biologics License Application for Linvoseltamab	08-20	CI
Regeneron Says FDA Turns Down Application for Blood-Cancer Treatment	08-20	DJ
Regeneron Pharmaceuticals Insider Sold Shares Worth $12,552,285, According to a Recent SEC Filing	08-19	MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $884,520, According to a Recent SEC Filing	08-19	MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $7,337,505, According to a Recent SEC Filing	08-15	MT
Switzerland's Sandoz Obtains US FDA Approval for Eylea Biosimilar	08-12	MT
Argus Raises Price Target on Regeneron Pharmaceuticals to $1,175 From $1,170	08-08	MT
Deutsche Bank Raises Price Target on Regeneron Pharmaceuticals to $990 From $870	08-02	MT

Chart Regeneron Pharmaceuticals, Inc.

Duration

Period

More charts

Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (56.6%); - revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%); - other (3%): primarily revenues from sales of technology licenses and subcontracted research services. At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.

Employees

13,926

Sector

Biotechnology & Medical Research

Calendar

14/09/2024 - European Society for Medical Oncology Meeting - Poster No: #1302P

Related indices

S&P 500

More about the company